JHVEPhoto/iStock Editorial via Getty Images Cancer drug developer I-Mab ( IMAB ) on Wednesday announced a clinical trial and supply agreement with Bristol Myers Squibb ( NYSE: BMY ) to study its bispecific antibody givastomig developed with Korean biotech ABL Bio. Per the terms, Bristol Myers ( BMY ) will supply its PD-L1-targeting immune checkpoint inhibitor, nivolumab, (Opdivo) to evaluate its antitumor effects in combination with givastomig and chemotherapy in a Phase 1 trial. The global trial is designed to evaluate the drug combo as a first-line option in certain patients with gastric and esophageal cancers.
I-Mab ( IMAB ) said the deal followed favorable safety and efficacy data the company posted for givastomig monotherapy at the European Society of Medical Oncology Congress 2023. “We remain optimistic that givastomig in combination with nivolumab and chemotherapy will drive potent anti-tumor activity in specific tumors, and we look forward to accelerating progress in the clinic,” I-MAB ( IMAB ) CEO Raj Kannan remarked. More on Bristol-Myers Squibb Bristol-Myers: Why I Am Buying More Of This Falling Knife, Yielding 5.
84% Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Bristol's Opdivo + Yervoy bests Lenvima, Nexavar in first-line liver cancer Bristol's Breyanzi demonstrates efficacy across a range of B-cell malignancies.
